Floatz logo

Dehydroepiandrosterone

Postmenopausal Atrophic Vaginitis

University Hospital, GhentSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Postmenopausal Atrophic Vaginitis cohort.

Asset / SponsorPhaseRating
Estriol
ITF Research Pharma, S.L.U.
Phase 2BB
Pilocarpinum
Alliance for Clinical Trials in Oncology
Phase 3BB
Autologous Conditioned Plasma
University of Miami
Phase 2B
Dhea
Hadassah Medical Organization
Phase 2/3B
Polycarbophil
University of Arkansas
Phase 2CCC
Testosterone Undecylate
Creighton University
Early Phase 1CC
Promestriene
Federal University of São Paulo
N/AD

Same molecule, other indications

Dehydroepiandrosterone is also rated in:

systemic lupus erythematosusDormant
BB
Indicative · Phase 3
66 / 100
View asset →
breast cancerActive
B
Indicative · Phase 4
61 / 100
View asset →
female reproductive organ cancerActive
B
Indicative · Phase 3
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →